Modelled DT Structure
Method: multi-sequence alignment based machine learning
Detail: Structure Info
General Information of DT | |||||
---|---|---|---|---|---|
DT ID | DTD0311 | ||||
Gene Name | SLC35F6 | ||||
Protein Name | ANT2-binding protein | ||||
Gene ID | |||||
UniProt ID | |||||
TCDB ID | |||||
3D Structure |
Modelled DT Structure Method: multi-sequence alignment based machine learning Detail: Structure Info |
||||
Synonyms | ANT2BP; C2orf18; SLC35F6; Solute carrier family 35 member F6; TANGO9; Transport and Golgi organization 9 homolog; UNQ3047/PRO9863 | ||||
DT Family | Drug/Metabolite Transporter (DMT) Superfamily | ||||
CMP-Sialate:CMP Antiporter (CSA) Family | |||||
Tissue Specificity | Expressed in pancreatic ductal adenocarcinoma(PDAC) (at protein level). Strongly expressed in prostate andthyroid. Weakly expressed in lung, heart, liver and kidney. | ||||
Function | This transporter is involved in maintaining mitochondrial membrane potential of pancreatic ductal adenocarcinoma (PDAC) cells. Promote the growth of pancreatic ductal adenocarcinoma (PDAC) cells. May play the role of nucleotide sugar transporter. | ||||
Endogenous Substrate(s) | Nucleotide-sugar | ||||
Variability Data of This Drug Transporter (DT) | |||||
Regulatory Variability Data of This DT (VARIDT 3.0) |
|||||
(β) Post-translational Modification of This DT |
|||||
(γ) Transcriptional Regulation of This DT |
|||||
(δ) Epigenetic Regulation of This DT |
|||||
General Variability Data of This DT (VARIDT 1.0) |
|||||
(β) Disease-specific Protein Abundances of This DT |
|||||
(γ) Species- and Tissue-specific DT Abundances |
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.